Stentys has announced that four-month data from its APPOSITION IV study, for its self-apposing stent, will be presented at the annual Transcatheter Cardiovascular Therapeutics (TCT) conference next week (27 October–1 November, San Francisco, USA).
A company press release reports that Robert-Jan van Geuns of Erasmus MC (Rotterdam, the Netherlands) and co-principal investigator will present “Sirolimus-eluting Self-Apposing stent: preliminary results of the APPOSITION IV study and future developments” during a satellite symposium on 29 October at 7:00am.
Additionally, the self-apposing stent will also be featured in multiple presentations throughout the congress, including results on series of patients outside of its acute myocardial infarction indication. For example, results of the OPEN II trial, a 200 patient European study evaluating the self-apposing drug-eluting stent in the treatment of coronary bifurcation lesions will be presented by the principal investigator of the study Christoph K Naber of the Contilia Heart and Vascular Center (Essen, Germany) on 28 October at 4:30pm.
